What the FDA labels say about taking them together
Oxybutynin and rivastigmine
Rivastigmine's FDA label of June 19, 2024 names oxybutynin in its drug interactions section; the oxybutynin labels PlainMeds reads (2) do not name rivastigmine. The rivastigmine label: “Rivastigmine tartrate may increase the cholinergic effects of other cholinomimetic medications and may also interfere with the activity of anticholinergic medications.”
Check it at the source: the oxybutynin FDA label on DailyMed (effective December 16, 2025, Accord Healthcare, Inc.); the rivastigmine FDA label on DailyMed (effective June 19, 2024, Aurobindo Pharma Limited).
What does the oxybutynin label say about rivastigmine?
Oxybutynin's label (effective December 16, 2025) and its 1 other brand-application label do not name rivastigmine in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (oxybutynin chloride), Accord Healthcare, Inc., effective December 16, 2025 (SPL set 61496a1e-17bf-4f45-a20c-5bb98fe545ee), via openFDA; the full label on DailyMed
What does the rivastigmine label say about oxybutynin?
Rivastigmine label, drug interactionsRivastigmine tartrate may increase the cholinergic effects of other cholinomimetic medications and may also interfere with the activity of anticholinergic medications (e.g., oxybutynin, tolterodine).
Source: FDA drug label (Exelon, NDA022083), Sandoz Inc, effective May 8, 2024 (SPL set b6ed6d15-116d-4596-92ce-3414574d7ba0), via openFDA
Source: FDA drug label (Rivastigmine Tartrate), Aurobindo Pharma Limited, effective June 19, 2024 (SPL set c246a0e5-1e77-41ee-a7b3-384f21f2f2e0), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Oxybutynin | Rivastigmine | |
|---|---|---|
| Labeled for | Overactive bladder | Alzheimer's disease |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.048 per tablet 5 mg tablet | $0.164 per capsule 1.5 mg capsule |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once